Takeda Applies For MHLW Approval For Type 2 Diabetes Drug Alogliptin
This article was originally published in PharmAsia News
Executive Summary
Takeda applied for new drug approval for type 2 diabetes drug SYR-322 (alogliptin) Sept. 29 with Japan's Ministry of Health, Labor and Welfare. Developed by Takeda San Diego, a Takeda subsidiary created by the company's acquisition of U.S. bioventure company Syrrx, alogliptin is a dipeptidyl peptidase-4 inhibitor. Takeda submitted the NDA application without conducting a domestic Phase III trial in Japan. If approved, Takeda expects alogliptin to be the third major diabetes drug from the company after Actos (pioglitazone) and Basen (voglibose). (Click here for more - Japanese language